Pharmaceutical companies can focus on any range of factors or processes involved in drug design, development or manufacturing. Therapeutic companies can create products from chemicals and synthetic processes or employ biotechnology to derive solutions from natural elements.
Businesses in the space can also specialize in creating IT solutions to streamline operations and improve efficiency for pharmaceutical manufacturers and researchers. Israel has one of the world’s most technologically advanced market economies and a thriving pharmaceutical sector. Having established itself as a major player in the global pharmaceutical industry, many pharma innovators have headquartered their businesses there.
Though oncology drug development is the largest facet of Israel’s pharmaceutical market, there are many more areas that have gained traction within the Israeli pharma scene and these are the ones to know.
Israel Pharmaceutical Companies
- Teva Pharmaceuticals
- Purple Biotech
- OncoHost
- CytoReason
- PolyPid
- QuantHealth
- Chemomab
Top Pharmaceutical Companies in Israel
CytoReason offers an AI platform of computational disease models, providing a database that maps human diseases at a cellular level to help inform researcher decision-making across the drug development life cycle. The company’s platform helps scientists identify potential targets, prioritize indications and stratify patient populations, allows program leaders to compare drugs and provides executives with tools for managing and optimizing drug portfolios.
KAHR Medical is building a novel drug platform consisting of immunotherapeutic bi-functional fusion proteins. These proteins work to leverage the human immune system’s responses to target cancer indications. The company’s technology aims to promote better and safer therapeutic avenues by developing new drugs that unmask cancer camouflage mechanisms.
Redhill Biopharma works to advance the treatment of gastrointestinal disorders through its pipeline of advanced clinical-stage drug candidates. Its products include Talicia, a capsule containing omeprazole, amoxicillin and rifabutin that treats Helicobacter pylori infection in adults, and Aemcolo, a rifamycin antibacterial for treating travelers’ diarrhea.
Chemomab develops therapeutics for fibro-inflammatory diseases. Its dual-activity monoclonal antibody neutralizes the activity of CCL24, the soluble protein that promotes fibrosis, and works to address the high unmet need for effective treatments in the space. The clinical-stage company believes its product could potentially interrupt the deleterious pathological processes that drive fibro-inflammatory diseases.
Purple Biotech is a clinical-stage oncology therapy company developing solutions to help patients overcome tumor immune evasion and drug resistance. Its pipeline includes a dual inhibitor, novel small molecule that targets oncogenic drivers, a humanized monoclonal antibody and a preclinical, conditionally-activated tri-specific antibody.
Pain Reform offers an extended-release drug-delivery system, intended to provide post-surgical patients with an extended period of pain relief following their operations. It aims to eliminate the need for administering repeated doses of pain medication and reduce the potential need for opiates. The company incorporates safe and effective generic drugs into its proprietary delivery system.
PolyPid is a clinical-stage pharmaceutical manufacturing company specializing in locally administered therapies that help improve surgical outcomes. Its polymer-lipid encapsulation matriX technology solution anchors in the surgical site to continually deliver medications in a controlled manner over the span of several days or months.
Pangea Biomed is a precision oncology company with solutions that combine molecular biology technology with bioinformatics and machine learning. Pangea provides a product for AI-enabled drug development that helps with identifying drug targets, finding optimal partner drugs, guiding clinical trials with biomarkers and more. It also offers tools for treatment nomination.
Datos Health offers an AI-driven remote patient monitoring solution. Its open-care platform allows clinicians to adjust workflows to their needs and protocols to create remote care programs or implement existing protocols from healthcare organizations. The workflows become patient CareApps that guide patients through automated assisted self-care. Datos Health records a 50 percent reduction in time for medication titration because of its platform.
OCON Therapeutics develops intra-uterine medical solutions using its proprietary IUB tech platform. One of its products is ball-shaped and uses Nitinol, a highly elastic alloy, to deliver long-lasting hormone-free contraception and other drugs into a patient’s body. Alongside its contraceptive product, OCON is in the clinical trial stage for disposable therapy that aims to treat abnormal uterine bleeding.
Omnix Medical develops and commercializes antibiotic agents that combat resistant pathogenic bacterial strains. This solution is particularly useful for those with chronic conditions and in modern hospital settings. Its agents are based on natural antimicrobial peptides and are genetically engineered to be compatible as therapeutics.
ApoWiser is a digital pharmacist solution that helps automate patient self-care. ApoWiser provides personalized guidance on over-the-counter drugs and delivers science-based, individualized recommendations. Its tech integrates with health provider and pharmacy chain platforms including Super-pharm, Superdrug and Maccabi healthcare services.
EPM Therapeutics is a pharmaceutical manufacturing company that develops synthetic cannabinoid acid derivatives. It aims to improve the symptoms of hyperphagia, or uncontrolled appetite, in patients with Prader-Willi Syndrome. Its lead drug candidate, EPM301, was granted lead Orphan Drug Designation by the U.S. FDA for treating patients with this condition.
RDD Pharma develops and commercializes therapeutics for anorectal diseases and gastrointestinal disorders. The company’s therapeutics are based on approved molecules with established safety and toxicity profiles, and the models it has in development are slated to reach the market in two to six years. RDD also offers its Capository delivery system for precisely administering molecules that target conditions in the anorectal region.
AION Labs is a biotechnology researcher and venture studio focused on creating and adopting AI technologies that modernize drug discovery and development. It enables scientist-founders to collaborate with global pharmaceutical leaders to accelerate the creation and validation of modern biotech solutions. Its portfolio features startups specializing in dynamic protein design, tailored antibody optimization, molecular glue discovery and other areas.
SuperTrans Medical is a biopharmaceutical innovator that develops antibiotics to target difficult-to-treat, multidrug-resistant bacteria. As antimicrobial resistance has become recognized as a global health threat, SuperTrans Medical is working to repurpose existing FDA-approved drug molecules to engineer superior properties in them.
VYNE Therapeutics develops treatments for immuno-inflammatory conditions, working to improve the lives of those with autoimmune diseases. The company’s pipeline includes an inhibitor platform for proteins believed to play a key role in regulating inflammatory and oncogenic genes involved in several diseases.
Teva Pharmaceuticals delivers medicines to patients with chronic conditions. It offers therapies for respiratory conditions like asthma and neurodegenerative conditions like multiple sclerosis. Teva also develops medicines for migraines as well as the oncology sector. The company employs about 37,000 people across 58 markets, working to discover treatments that can improve one’s quality of life.
QuantHealth is a research company working to reduce the risk involved with drug development. The company conducts patient-centric drug simulations that allows pharmaceutical and biotechnology organizations to run thousands of variations of their clinical trials quickly, enabling them to optimize trial design, increase success rates and discover new clinical opportunities.
OncoHost is a precision medicine company offering a plasma-based, proteomic pattern analysis tool for the non-small cell lung cancer space. The platform uses a patient blood sample to help guide clinicians as to what the optimal first-line immunotherapy treatment plan should be per patients’ individual needs. The company has a prospective clinical trial with over 40 sites with 1,700 patients recruited to participate.
